M. Macdougall

发表

VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

Rachel Kroe-Barrett, Sanjaya Singh, Jennifer Ahlberg, 2020, mAbs.

Non-neutralizing antibodies increase endogenous circulating Ang1 levels

R. Fryer, Rachel Kroe-Barrett, Sanjaya Singh, 2018, mAbs.

Generation and characterization of a monoclonal IgG antibody to polyethylene glycol.

K. Lumb, H. Vasavada, M. Macdougall, 2007, Hybridoma.

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Michael D. Hamilton, J. Pfefferkorn, N. Barucci, 2012, Bioorganic & medicinal chemistry letters.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Role of the Glucagon Receptor COOH-Terminal Domain in Glucagon-Mediated Signaling and Receptor Internalization

J. Livingston, H. Yoo-Warren, J. Buggy, 1997, Diabetes.

Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.

A. Carlo, J. Pfefferkorn, J. Litchfield, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.

J. Livingston, E. Doherty, M. Macdougall, 2002, Bioorganic & medicinal chemistry letters.

Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist*

C. Pan, J. Buxton, T. Claus, 2006, Journal of Biological Chemistry.

Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice

R. Fryer, M. McHugh, Heather N Robinson, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.

J. Livingston, J. Jones, M. Bobko, 2002, Bioorganic & medicinal chemistry letters.

Discovery of 5‐Hydroxyalkyl‐4‐phenylpyridines as a New Class of Glucagon Receptor Antagonists.

J. Livingston, E. Doherty, M. Macdougall, 2002 .

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

J. Treadway, J. Baker, M. McDowell, 2011, BMC Genomics.

Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.

J. Livingston, J. Jones, Roger A. Smith, 2002, Bioorganic & medicinal chemistry letters.

Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide*

C. Pan, S. Roczniak, Stephanie L. Yung, 2003, The Journal of Biological Chemistry.

PDE-10A inhibitors as insulin secretagogues.

Lei Zhu, J. Livingston, T. Claus, 2007, Bioorganic & medicinal chemistry letters.